Zobrazeno 1 - 10
of 73
pro vyhledávání: '"BUZDAR, A"'
Autor:
Gregory D. Jenkins, Sandhya Devarajan, Junmei Cairns, Erin E. Carlson, Anthony Batzler, Matthew P. Goetz, Tanda M. Dudenkov, Aman U. Buzdar, Michiaki Kubo, Yongxian Zhuang, Joel M. Reid, Alvaro Moreno-Aspitia, Poulami Barman, Mark E. Robson, Liewei Wang, Krishna R. Kalari, Richard M. Weinshilboum, James N. Ingle, Duan Liu, Zeruesenay Desta, Donald W. Northfelt
Publikováno v:
Clinical Pharmacology & Therapeutics. 106:219-227
Anastrozole is a widely prescribed aromatase inhibitor for the therapy of estrogen receptor positive (ER+) breast cancer. We performed a genome-wide association study (GWAS) for plasma anastrozole concentrations in 687 postmenopausal women with ER+ b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Christopher Zergebel, Lee S. Schwartzberg, Bill Kimball, August Garin, Aman U. Buzdar, Michele Houghton, Alejandra T. Perez, C Vogel, James N. Ingle
Publikováno v:
Cancer. 118:3244-3253
BACKGROUND: The objective of this study was to evaluate 3 different doses of (7α)-21-(4-[(diethylamino)methyl]-2 methoxyphenoxy)-7 methyl-19 norpregna-1,3,5(10)-trien-3-ol 2-hydroxy-1,2,3-propanetricarboxylate (TAS-108) in patients with recurrent, h
Autor:
Soon Tae Park, Aman U. Buzdar, Angelo Di Leo, Francisco J. Esteva, Eun-Jung Jung, Ju-Yeon Kim, George A. Calin, Xiao Feng Le, Erica Moretti, Robert C. Bast, Lajos Pusztai, Libero Santarpia
Publikováno v:
Cancer. 118:2603-2614
BACKGROUND Trastuzumab is part of the standard treatment for HER-2 positive breast cancer patients, but not all patients respond to trastuzumab. Altered expression levels for microRNAs in cancer cells have been correlated with prognosis and response
Autor:
Aman U. Buzdar, Funda Meric-Bernstam, Ana M. Gonzalez-Angulo, Gabriel N. Hortobagyi, Soley Bayraktar, Xiudong Lei, Aysegul A. Sahin, Henry Mark Kuerer, Vicente Valero, Amal Melhem-Bertrandt
Publikováno v:
Cancer. 118:2385-2393
Background To evaluate the pathologic complete response (pCR) rates and relapse-free survival (RFS) and overall survival (OS) of patients receiving neoadjuvant systemic therapy (NST) with trastuzumab in combination with an anthracycline- or a non-ant
Autor:
Yvette DeJesus, Aman U. Buzdar, Laura Boehnke Michaud, Lee Cheng, Maria Alma Rodriguez, Alessandra Ferrajoli
Publikováno v:
Cancer. 117:3268-3275
In 2007, the US Food and Drug Administration (FDA) issued regulatory alerts for use of erythropoiesis-stimulating agents (ESAs) in cancer patients with anemia after clinical trials and meta-analysis data found that high ESA doses were associated with
Autor:
Luis M Vence, Funda Meric-Bernstam, Kelly K. Hunt, Aman U. Buzdar, William Fraser Symmans, Henry Mark Kuerer, Anthony Lucci, Laszlo Radvanyi, Elizabeth A. Mittendorf, Francisco J. Esteva
Publikováno v:
Cancer. 117:39-47
BACKGROUND: Through this study, the authors sought to investigate the biologic and immunologic effects of preoperative trastuzumab in patients with ductal carcinoma in situ (DCIS) of the breast. METHODS: Patients with DCIS were enrolled in this open-
Autor:
Vicente Valero, Peter F. Thall, Andrew D. Seidman, Kristine Broglio, Susan G. Arbuck, Frankie A. Holmes, Aman U. Buzdar, Anthony W. Tolcher, Gabriel N. Hortobagyi, Stacy L. Moulder
Publikováno v:
Cancer. 116:814-821
Purpose To compare efficacy and toxicity profiles of paclitaxel using 3-hour versus 96-hour infusion schedules.
Autor:
Angela Brodie, Jo Anne Zujewski, R. Charles Coombes, Aman U. Buzdar, Kathleen I. Pritchard, Eric P. Winer, James N. Ingle, William R. Miller, Paul E. Goss, Steven E. Come, Stephen R. D. Johnston
Publikováno v:
Cancer. 112:673-678
The Sixth Cambridge Conference on Endocrine and Targeted Manipulation of Breast Cancer was convened in Cambridge, Massachusetts on April 30 and May 1, 2007. The purpose of this multidisciplinary meeting of leaders in clinical and basic research and p
Autor:
Francisco J. Esteva, Lajos Pusztai, Kristine Broglio, Chafika Mazouni, Angeline Hall, Herbert A. Fritsche, Massimo Cristofanilli, Gabriel N. Hortobagyi, Aman U. Buzdar, Fabrice Andre
Publikováno v:
Cancer. 109:496-501
BACKGROUND. The purpose of the study was to determine the utility of quantitation of the extracellular domain (ECD) of the HER-2/neu receptor in the serum for predicting response to treatment in patients with primary breast cancer receiving neoadjuva